Back to Agenda
Session 8: The VALID Act
Session Chair(s)
Carly McWilliams, MBA
Head of Regulatory Policy, Roche Diagnostics, United States
Lakshman Ramamurthy, PHD
Head of Global Regulatory, Precision Medicine and Digital Health, GlaxoSmithKline, United States
The VALID Act of 2021 (VALID 2021), introduced by Senators Bennett and Burr and Representatives Buschon and DeGette in June 2021, is the latest legislative effort for comprehensive diagnostic regulatory reform. Specially designed for in vitro diagnostics, VALID 2021 is the culmination of years of efforts to reach agreement on a risk and activity based regulatory paradigm in this session, we will hear directly from the staff leading the VALID 2021 legislative effort on their policy priorities and the legislative path forward.
*NOTE – THIS SESSION WILL NOT BE AVAILABLE ON-DEMAND
Learning Objective : At the conclusion of this session, participants should be able to:
- Explain the VALID Act 2021 and the proposed regulatory paradigm for in vitro clinical tests
- Discuss how VALID 2021 will advance patient and public health and the diagnostic industry overall
- Discuss the importance and methods for advancing the VALID Act through Congress and into law
Speaker(s)
Sherie Lou Santos, MPH
Health Policy Director for Representative Diana DeGette (D-CO-01), U.S. House of Representatives, United States
Speaker
Santiago Gonzalez, MPH
Senior Policy Advisor for Senator Michael Bennet, U.S. Senate, United States
Speaker
Dylan Moore
Deputy Chief of Staff and Legislative Director for Representative Larry Buschon, U.S. House of Representatives, United States
Speaker
Angela Wiles
Health Policy Director, Senate Health, Education, Labor and Pensions Committee, United States
Speaker
Have an account?